[Gastrointestinal infections].

C Lübbert, R Mutters
Author Information
  1. C Lübbert: Fachbereich Infektions- und Tropenmedizin, Klinik und Poliklinik für Gastroenterologie und Rheumatologie, Department für Innere Medizin, Neurologie und Dermatologie, Universitätsklinikum Leipzig AöR, Liebigstr. 20, 04103, Leipzig, Deutschland. christoph.luebbert@medizin.uni-leipzig.de.
  2. R Mutters: Institut für Medizinische Mikrobiologie und Krankenhaushygiene, Philipps-Universität Marburg, Marburg, Deutschland.

Abstract

Infectious diarrhea is one of the most common diseases. This article summarizes the current state of the diagnostics and treatment and includes the most important pathogens, i.e. Norovirus, Rotavirus, Campylobacter, Salmonella, Shigella and pathogenic Escherichia coli. Infections caused by toxin-producing strains of Clostridium difficile are described in more detail due to the increasing importance. Symptomatic therapy is still the most important component of treatment. Empirical antibiotic therapy is reserved for severely ill patients with a high stool frequency, fever, bloody diarrhea, underlying immune deficiency or significant comorbidities. Increasing bacterial resistance (in particular against fluoroquinolones) has to be considered. Motility inhibitors are not recommended for infections due to Shiga toxin-producing E. coli, C. difficile infections (CDI) and severe enterocolitis caused by other pathogens. The macrocyclic antibiotic fidaxomicin can reduce the recurrence rate of CDI. Fecal microbiota transplantation (FMT) currently provides a reserve treatment option for multiple recurrences of CDI and is subject to the Medicines Act (Arzneimittelgesetz, AMG) in Germany.

Keywords

References

  1. Cochrane Database Syst Rev. 2012 Dec 12;12 :CD007787 [PMID: 23235648]
  2. N Engl J Med. 2011 Nov 10;365(19):1763-70 [PMID: 22029753]
  3. Infect Dis Clin North Am. 2015 Dec;29(4):617-35 [PMID: 26337738]
  4. Lancet. 2012 Jun 30;379(9835):2466-76 [PMID: 22748592]
  5. Infect Dis Clin North Am. 2012 Jun;26(2):323-39 [PMID: 22632642]
  6. Curr Opin Gastroenterol. 2011 Jan;27(1):1-7 [PMID: 21124212]
  7. Cochrane Database Syst Rev. 2012 Nov 14;11:CD001167 [PMID: 23152205]
  8. JAMA. 1990 Feb 16;263(7):979-82 [PMID: 2299766]
  9. Internist (Berl). 2015 Dec;56(12):1353-60 [PMID: 26573083]
  10. BMJ. 2012 Jul 19;345:e4565 [PMID: 22815429]
  11. JAMA. 2014 Nov 5;312(17):1772-8 [PMID: 25322359]
  12. N Engl J Med. 2003 Apr 17;348(16):1565-73 [PMID: 12700377]
  13. N Engl J Med. 2013 Jan 31;368(5):407-15 [PMID: 23323867]
  14. N Engl J Med. 2010 Jan 21;362(3):197-205 [PMID: 20089970]
  15. Clin Infect Dis. 2003 Nov 1;37(9):1165-71 [PMID: 14557959]
  16. JAMA. 2015 Jan 6;313(1):71-80 [PMID: 25562268]
  17. Z Gastroenterol. 2015 May;53(5):418-59 [PMID: 25965989]
  18. Antimicrob Agents Chemother. 2011 Dec;55(12):5939-41 [PMID: 21911571]
  19. Clin Microbiol Infect. 2015 Mar;21(3):248.e9-248.e16 [PMID: 25701178]
  20. Eur J Clin Microbiol Infect Dis. 2015 Dec;34(12):2325-30 [PMID: 26377204]
  21. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD004932 [PMID: 17253532]
  22. Cochrane Database Syst Rev. 2010 Nov 10;(11):CD003048 [PMID: 21069673]
  23. N Engl J Med. 1989 Jul 6;321(1):16-24 [PMID: 2659991]
  24. Clin Infect Dis. 2015 Mar 15;60(6):837-46 [PMID: 25613287]
  25. Clin Microbiol Infect. 2014 Mar;20 Suppl 2:1-26 [PMID: 24118601]
  26. Internist (Berl). 2013 Nov;54(11):1383-92 [PMID: 23974914]
  27. Dtsch Arztebl Int. 2016 Sep 5;113(35-36):583-9 [PMID: 27658471]
  28. Expert Opin Pharmacother. 2004 Aug;5(8):1727-35 [PMID: 15264987]
  29. JAMA. 2012 Mar 14;307(10):1046-52 [PMID: 22416100]
  30. JAMA. 2015 May 5;313(17):1719-27 [PMID: 25942722]
  31. Clin Microbiol Rev. 2015 Jan;28(1):134-64 [PMID: 25567225]
  32. Cochrane Database Syst Rev. 2010 Aug 04;(8):CD006784 [PMID: 20687081]
  33. Infect Disord Drug Targets. 2010 Aug;10(4):283-94 [PMID: 20429863]
  34. Int J Med Microbiol. 2015 Jan;305(1):148-56 [PMID: 25547265]
  35. Pediatr Infect Dis J. 2012 Jan;31(1):37-41 [PMID: 21892124]
  36. Dtsch Arztebl Int. 2014 Oct 24;111(43):723-31 [PMID: 25404529]
  37. Ann Intern Med. 1992 Aug 1;117(3):202-8 [PMID: 1616214]
  38. N Engl J Med. 2011 Feb 3;364(5):422-31 [PMID: 21288078]
  39. Therap Adv Gastroenterol. 2011 Jul;4(4):227-35 [PMID: 21765867]
  40. Arch Pathol Lab Med. 1996 Feb;120(2):206-11 [PMID: 8712901]
  41. N Engl J Med. 2004 Jan 1;350(1):38-47 [PMID: 14702426]
  42. Z Gastroenterol. 2014 Jun;52(6):549-57 [PMID: 24905106]
  43. Internist (Berl). 2013 Dec;54(12):1513-9 [PMID: 23917963]
  44. J Clin Microbiol. 2007 Feb;45(2):678-9 [PMID: 17122011]
  45. Expert Rev Anti Infect Ther. 2016;14 (2):193-206 [PMID: 26641310]

MeSH Term

Anti-Bacterial Agents
Antiviral Agents
Bacterial Infections
Diagnosis, Differential
Diarrhea
Evidence-Based Medicine
Gastrointestinal Diseases
Humans
Symptom Assessment
Treatment Outcome
Virus Diseases

Chemicals

Anti-Bacterial Agents
Antiviral Agents